logo

For the Inventor, By the Inventor

Indianapolis, IN, United States of America

Paul D Gesellchen

This inventor holds 11 USPTO granted patents. Top assignee: Eli Lilly and Company. Active years: 1981-1995.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Paul D Gesellchen. Retrieved from https://idiyas.com/inventor/paul-d-gesellchen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 11

% Patents Active = 100.0

Average Co-Inventor Count = 1.9

ph-index = 8

Forward Citations = 124(Granted Patents)


Company Filing History:

goldMedal11 out of 4,520 
 
Eli Lilly and Company
 patents

Years Active: 1981-1995

Loading Chart...
11 patents (USPTO):Explore Patents
1. 5430023 - Tripeptide antithrombotic agents (1995-07-04),
2. 5422426 - Rapid synthesis and screening of peptide mimetics (1995-06-06),
3. 4510082 - Pharmacologically active peptides (1985-04-09),
4. 4473497 - Pharmacologically active peptides (1984-09-25),
5. 4351763 - Pharmacologically active peptides (1982-09-28),
6. 4322340 - Pharmacologically active peptides (1982-03-30),
7. 4322339 - Pharmacologically active peptides (1982-03-30),
8. 4309343 - Pharmacologically active peptides (1982-01-05),
9. 4283329 - Pharmacologically active peptides (1981-08-11),
10. 4265808 - Pharmacologically active peptides (1981-05-05),
11. 4251439 - Pharmacologically active peptides (1981-02-17),

Title: The Innovative Mind of Paul D. Gesellchen

Introduction

Paul D. Gesellchen is an accomplished inventor based in Indianapolis, IN, with a remarkable portfolio that includes 11 patents. His innovative contributions mainly focus on developing advanced medical solutions, particularly in the field of thrombin inhibitors and peptide synthesis.

Latest Patents

Among his latest patents is a formulation of tripeptide antithrombotic agents. This includes thrombin inhibitors represented by a complex chemical structure, where various groups are incorporated to enhance their effectiveness in inhibiting blood clot formation. Additionally, Paul has developed a method for the rapid synthesis and screening of peptide mimetics. This novel approach allows for the rapid production of large numbers of peptides, facilitating efficient identification of those that exhibit biological activity through a minimal number of coupling steps.

Career Highlights

Paul's career is prominently marked by his role at Eli Lilly and Company, where he has contributed to pivotal advancements in pharmaceutical formulations. His extensive research has not only paved the way for innovative therapeutics but also strengthened intellectual properties within the company.

Collaborations

Throughout his career, Paul has collaborated with notable colleagues, including Robert T. Shuman and David L. Smiley. These partnerships have fostered creativity and innovation, allowing for the sharing of ideas and expertise in their respective fields.

Conclusion

Paul D. Gesellchen continues to be a significant figure in the realm of medical innovations. His dedication to advancing pharmaceutical science through his numerous patents highlights his invaluable contribution to healthcare and biochemistry. Through his inventive spirit, Paul remains at the forefront of developing solutions that aim to improve patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…